Zepatier
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Elbasvir;grazoprevir
- Made by
- Merck Sharp & Dohme B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- ZEPATIER is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg (see sections 4.2, 4.4 and 5.1). For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
Details
| Made by | Merck Sharp & Dohme B.V. |
|---|---|
| Active substance | Elbasvir;grazoprevir |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J05AP54 · Antibiotics, antivirals and antifungals taken into the body |
| Authorised on | 2016-07-22 |
| Last updated by the regulator | 2025-11-07 |
| EMA product number | EMEA/H/C/004126 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).